Xiaoyan Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoyan Ding has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Watts
University of Oxford, Oxford, UK
1 shared publication Bin Bin Xie
Lieber Institute for Brain Development, Johns Hopkins University, Baltimore, MD 21205, USA
1 shared publication- Bingqing He
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; State Key Laboratory of Drug Research, The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China
1 shared publication Borjigin Uyunbilig
The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot 010021, China
1 shared publication- Chao Sun
Department of Communication Science and Engineering, Key Laboratory of EMW Information (MoE), Fudan University, Shanghai, China
1 shared publication - Chenghai Liu
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication
Latest Publications
- 3 November 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 224 (1)
Bcl11a preserves hematopoietic stem cell function in culture by restraining Ncf1-dependent ROS
Ex vivo expansion of hematopoietic stem cells (HSCs) is limited by culture-induced oxidative stress, yet the upstream transcriptional drivers remain poorly defined. Here, we show that the transcription factor Bcl11a is rapidly and persistently downregulated during HSC culture and that this decline drives functional deterioration. Bcl11a was both required and sufficient to maintain quiescence, clonogenic activity, and serially transplantable HSC function. Mechanistically, Bcl11a directly represses a Nox2 NADPH oxidase gene module, including Ncf1, encoding the p47phox organizer subunit; Ncf1 deletion reduced ROS and partially rescued the defects of Bcl11a-deficient HSCs. Rapamycin—but not the ROS scavenger N-acetylcysteine—restored Bcl11a expression, suppressed Ncf1 and ROS, and improved HSC function, identifying Bcl11a as a candidate effector linking mechanistic target of rapamycin complex 1 inhibition to redox control. This axis was conserved in human hematopoietic stem and progenitor cells, revealing a druggable transcriptional vulnerability of cultured HSCs and a framework for improving ex vivo–expanded grafts.
- 3 November 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 224 (1)
Bcl11a preserves hematopoietic stem cell function in culture by restraining Ncf1-dependent ROS
Ex vivo expansion of hematopoietic stem cells (HSCs) is limited by culture-induced oxidative stress, yet the upstream transcriptional drivers remain poorly defined. Here, we show that the transcription factor Bcl11a is rapidly and persistently downregulated during HSC culture and that this decline drives functional deterioration. Bcl11a was both required and sufficient to maintain quiescence, clonogenic activity, and serially transplantable HSC function. Mechanistically, Bcl11a directly represses a Nox2 NADPH oxidase gene module, including Ncf1, encoding the p47phox organizer subunit; Ncf1 deletion reduced ROS and partially rescued the defects of Bcl11a-deficient HSCs. Rapamycin—but not the ROS scavenger N-acetylcysteine—restored Bcl11a expression, suppressed Ncf1 and ROS, and improved HSC function, identifying Bcl11a as a candidate effector linking mechanistic target of rapamycin complex 1 inhibition to redox control. This axis was conserved in human hematopoietic stem and progenitor cells, revealing a druggable transcriptional vulnerability of cultured HSCs and a framework for improving ex vivo–expanded grafts.
- 5 November 2023
- Published by MyJove Corporation
- No. 201,p. e65888
JoVE Video Dataset
Retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) are superior cell sources for cell replacement therapy in individuals with retinal degenerative diseases; however, studies on the stable and secure banking of these therapeutic cells are scarce. Highly variable cell viability and functional recovery of RPE cells after cryopreservation are the most commonly encountered issues. In the present protocol, we aimed to achieve the best cell recovery rate after thawing by selecting the optimal cell phase for freezing based on the original experimental conditions. Cells were frozen in the exponential phase determined by using the 5-ethynyl-2′-deoxyuridine labeling assay, which improved cell viability and recovery rate after thawing. Stable and functional cells were obtained shortly after thawing, independent of a long differentiation process. The methods described here allow the simple, efficient, and inexpensive preservation and thawing of hESC-derived RPE cells. Although this protocol focuses on RPE cells, this freezing strategy may be applied to many other types of differentiated cells.
- 5 November 2023
- Published by MyJove Corporation
- No. 201,p. e65888
JoVE Video Dataset
Retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) are superior cell sources for cell replacement therapy in individuals with retinal degenerative diseases; however, studies on the stable and secure banking of these therapeutic cells are scarce. Highly variable cell viability and functional recovery of RPE cells after cryopreservation are the most commonly encountered issues. In the present protocol, we aimed to achieve the best cell recovery rate after thawing by selecting the optimal cell phase for freezing based on the original experimental conditions. Cells were frozen in the exponential phase determined by using the 5-ethynyl-2′-deoxyuridine labeling assay, which improved cell viability and recovery rate after thawing. Stable and functional cells were obtained shortly after thawing, independent of a long differentiation process. The methods described here allow the simple, efficient, and inexpensive preservation and thawing of hESC-derived RPE cells. Although this protocol focuses on RPE cells, this freezing strategy may be applied to many other types of differentiated cells.
- Open Access
- 27 December 2022
- Published by Elsevier in Molecules and Cells
- Vol. 45 (12) , 923-934
The Aurora Kinase Inhibitor CYC116 Promotes the Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells
Sijia Ji, Wanzhi Tu, Chenwen Huang, Ziyang Chen, Xinyue Ren, Bingqing He, Xiaoyan Ding, Yuelei Chen, and Xin Xie. Mol. Cells 2022;45:923-34. https://doi.org/10.14348/molcells.2022.0077
- 27 December 2022
- Published by Elsevier in Molecules and Cells
- Vol. 45 (12) , 923-934
Open AccessThe Aurora Kinase Inhibitor CYC116 Promotes the Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells
Sijia Ji, Wanzhi Tu, Chenwen Huang, Ziyang Chen, Xinyue Ren, Bingqing He, Xiaoyan Ding, Yuelei Chen, and Xin Xie. Mol. Cells 2022;45:923-34. https://doi.org/10.14348/molcells.2022.0077
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 17a
Modulation of Energy Conversion Through Manipulation of the Retinal Thermal Equilibrium by an Aromatic Residue in the Seven-Transmembrane Receptor Bacteriorhodopsin
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 17a
Modulation of Energy Conversion Through Manipulation of the Retinal Thermal Equilibrium by an Aromatic Residue in the Seven-Transmembrane Receptor Bacteriorhodopsin
- Open Access
- 28 June 2012
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 4 (6) , 420-422
Genome-wide roles of Foxa2 in directing liver specification
Dear Editor,
- 28 June 2012
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 4 (6) , 420-422
Open AccessGenome-wide roles of Foxa2 in directing liver specification
Dear Editor,
- Open Access
- 25 February 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (5) , 1708-1718
Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes
Epithelial-mesenchymal transition (EMT) is a physiological process that has been recognized to occur during the progression of an increasingly large number of human diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. The activation of transforming growth factor β (TGF-β) signaling is considered a critical event during EMT, and efforts have been made to screen small molecules that interfere with the TGF-β signaling pathway during EMT. Here we report the identification of sorafenib, a clinical agent that inhibits TGF-β signaling. When applied to AML12 cells and primary hepatocytes, sorafenib strikingly suppressed TGF-β1-induced EMT and apoptosis. Additionally, sorafenib inhibited TGF-β1-induced signal transducer and activator of transcription 3 phosphorylation. We further present in vitro evidence that sorafenib ameliorates the proapoptotic and profibrotic effects of TGF-β1 in mouse primary hepatocytes, suggesting that this drug exerts a protective effect on hepatocytes and has therapeutic potential for the treatment of liver fibrosis. (Hepatology 2011;)
- 25 February 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (5) , 1708-1718
Open AccessSorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes
Epithelial-mesenchymal transition (EMT) is a physiological process that has been recognized to occur during the progression of an increasingly large number of human diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. The activation of transforming growth factor β (TGF-β) signaling is considered a critical event during EMT, and efforts have been made to screen small molecules that interfere with the TGF-β signaling pathway during EMT. Here we report the identification of sorafenib, a clinical agent that inhibits TGF-β signaling. When applied to AML12 cells and primary hepatocytes, sorafenib strikingly suppressed TGF-β1-induced EMT and apoptosis. Additionally, sorafenib inhibited TGF-β1-induced signal transducer and activator of transcription 3 phosphorylation. We further present in vitro evidence that sorafenib ameliorates the proapoptotic and profibrotic effects of TGF-β1 in mouse primary hepatocytes, suggesting that this drug exerts a protective effect on hepatocytes and has therapeutic potential for the treatment of liver fibrosis. (Hepatology 2011;)